The past 2 years have brought a decisive leap forward in the management of age-related macular degeneration.
Pharmacotherapies with increased efficacy and extended durability are allowing for more relaxed treatment schedules, and for the first time, treatment options for the atrophic stages of the disease have become available. At the same time, advances in AI and home monitoring are paving the way to more precise diagnosing and monitoring for truly personalized care, lessening the burden for both patients and health care providers.
“We have had more innovation in the past 2 years than in